Search
Nirsevimab is a long-acting monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in infants and high-risk children. During the 2024 RSV season in Western Australia, 21 922 doses were administered to infants entering their first season and 1221 doses to at-risk children. In this context, the selection and spread of escape variants are a potential concern. This study aimed to investigate nirsevimab binding site mutations using clinical and wastewater data.
Hannah Tom Moore Snelling OAM BSc (Hons) GradDipClinEpi PhD BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Diseases Research Head, Infectious
Hannah Moore OAM BSc (Hons) GradDipClinEpi PhD Head, Infectious Diseases Research 08 6319 1427 Hannah.moore@thekids.org.au Head, Infectious Diseases
The Western Australian Influenza Vaccine Effectiveness study commenced in 2008 to evaluate a new program to provide free influenza vaccine to all children...
Influenza vaccine was offered to all children aged 6-59 months resident in Western Australia in 2008, and we wished to evaluate the effectiveness of this immunisation programme.
We investigated trends in invasive pneumococcal disease (IPD) in Western Australia (WA).
To investigate temporal trends in admission rates for acute lower respiratory infections (ALRI) in a total population birth cohort of non-Aboriginal and...
Infection accounts for the majority of pediatric mortality and morbidity in developing countries, but there are limited data on the infectious diseases...
Christopher Kefyalew Hannah Blyth Alene Moore MBBS (Hons) DCH FRACP FRCPA PhD BSc, MPH, PhD OAM BSc (Hons) GradDipClinEpi PhD Centre Head, Wesfarmers
Christopher Deborah Blyth Lehmann MBBS (Hons) DCH FRACP FRCPA PhD AO, MBBS, MSc Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases;